NCT03515382

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers

A Phase I, Open-Label, Randomized, Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole and Voriconazole on the Single-Dose Pharmacokinetics of GLPG1690 in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Galapagos NV · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The sponsor wants to investigate how well the test medicine is taken up by the body when given alongside two other already approved medicines. This kind of study is known as a drug-drug interaction study. In this case the other medicines are itraconazole and voriconazole. The sponsor will also look at the safety and tolerability of the test medicine when taken alone, and when taken with the approved medicines.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	GLPG1690	A single oral dose of GLPG1690.
DRUG	Itraconazole	A single oral dose of itraconazole.
DRUG	Voriconazole	A single oral dose of voriconazole.

Timeline

• Start date: 2018-03-16
• Primary completion: 2018-06-01
• Completion: 2018-06-01
• First posted: 2018-05-03
• Last updated: 2018-06-11

Locations

1 site across 1 country: United Kingdom